Avidity Biosciences, Inc. — Director's Dealing 2022

Aug 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Avidity Biosciences, Inc. (RNA)
CIK: 0001599901
Period of Report: 2022-08-15

Reporting Person: Boyce Sarah (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-15	Common Stock	M	100	$1.24	Acquired	100	Direct
2022-08-15	Common Stock	S	100	$22.47	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-15	Stock Option (Right to Buy)	$1.24	M	100	Disposed	2029-12-17	Common Stock (100)	Direct

Footnotes

F1: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.